Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

160.90B

Market cap160.90B

Price-Earnings ratio

17.63

Price-Earnings ratio17.63

Dividend yield

2.46%

Dividend yield2.46%

Average volume

6.68M

Average volume6.68M

High today

$133.04

High today$133.04

Low today

$129.06

Low today$129.06

Open price

$132.27

Open price$132.27

Volume

6.64M

Volume6.64M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$100.23

52 Week low$100.23

Stock Snapshot

As of today, Gilead Sciences(GILD) shares are valued at $129.06. The company's market cap stands at 160.9B, with a P/E ratio of 17.63 and a dividend yield of 2.5%.

As of 2026-05-16, Gilead Sciences(GILD) stock has fluctuated between $129.06 and $133.04. The current price stands at $129.06, placing the stock 0.0% above today's low and -3.0% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 6.64M, against a daily average of 6.68M.

During the past year, Gilead Sciences(GILD) stock moved between $100.23 at its lowest and $157.29 at its peak.

GILD News

Simply Wall St 15h

A Look At Gilead Sciences Valuation After The Recent Share Price Pullback

Advertisement Stock performance snapshot and recent context Gilead Sciences (GILD) has seen its stock pull back recently, with the price declining about 7% ov...

Simply Wall St 3d

Gilead Liver Data At EASL Tests Case For A Third Growth Pillar

Gilead Sciences (NasdaqGS:GILD) plans to present new liver disease data at the upcoming EASL Congress. The company will showcase pivotal Phase 3 results for Li...

TipRanks 3d

Gilead to present new data on PBC, viral hepatitis at EASL 2026

Gilead (GILD) Sciences will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver Con...

Analyst ratings

75%

of 32 ratings

Buy

75%

Hold

21.9%

Sell

3.1%

More GILD News

Simply Wall St 6d

Did Gilead’s Mixed Q1, Buybacks and HIV Milestone Just Shift Gilead Sciences' Investment Narrative?

In early May 2026, Gilead Sciences reported first-quarter revenue of US$6.96 billion and net income of US$2.02 billion, while also completing a multi-year US$4....

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.